ORIC Pharmaceuticals, Inc. ORIC
8.91 USD -0.32 (-3.47%)
At closeNov 10, 2026, 4:01 PM EST
8.91 0.00 0.00%
After hours · Nov 10, 4:01 PM ET
8.76 Day range 9.45
7.47 52-week range 14.65
- YTD
- +8.92%
- 1 year
- -28.49%
News
globenewswire.com ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address…
globenewswire.com ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing…
benzinga.com BTIG Reiterates Buy on ORIC Pharmaceuticals, Maintains $26 Price Target BTIG analyst Jeet Mukherjee reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $26 price target.
benzinga.com Wedbush Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $14 Wedbush analyst David Nierengarten maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and lowers the price target from $17 to $14.
defenseworld.net Oric Pharmaceuticals (NASDAQ:ORIC) Stock Crosses Below 200-Day Moving Average – Should You Sell? Oric Pharmaceuticals, Inc. (NASDAQ: ORIC - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $11.14 and…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Surgery Partners (NASDAQ:SGRY) shares moved upwards by 46.9% to $23.14 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. SciSparc (NASDAQ:SPRC)…
benzinga.com Stifel Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $18 Stifel analyst Laura Prendergast maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $14 to $18.
seekingalpha.com ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Data and Commercial Opportunity in EGFR Atypical Non-Small Cell Lung Cancer Transcript ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Data and Commercial Opportunity in EGFR Atypical Non-Small Cell Lung Cancer Transcript
marketbeat.com Oric Pharmaceuticals' Enozertinib Shows 88% Response Rate in EGFR Lung Cancer Study Oric Pharmaceuticals NASDAQ: ORIC reported updated Phase 1b data for enozertinib in previously untreated patients with advanced non-small cell lung cancer (NSCLC) carrying atypical EGFR mutations,…
benzinga.com ORIC Plans Global Phase 3 Redwood-1 Trial Of Enozertinib In 1L EGFR Atypical NSCLC In 1H 2027 After Phase 1b Showing 84% Confirmed Systemic ORR, 70% Confirmed Intracranial ORR In a 1L EGFR atypical population with more than double the rate of baseline CNS metastases as competitor datasets, enozertinib demonstrates a potential best-in-class 84% confirmed systemic ORR and…
globenewswire.com ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial In a 1L EGFR atypical population with more than double the rate of baseline CNS metastases as competitor datasets, enozertinib demonstrates a potential best-in-class 84% confirmed systemic ORR and…
globenewswire.com ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026 Preclinical data highlight potential advantages of targeting PRC2 via EED over EZH2, including the emergence of resistance mutations to EZH2 inhibitors like mevrometostat and against which the EED…
globenewswire.com ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026 Conference call and webcast to take place on Friday, October 23, 2026, at 8:00 a.m. ET Event to feature Dr. Joshua Sabari to discuss enozertinib clinical data and the potential of enozertinib to…
benzinga.com Meta To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Wednesday Analysts raised targets for ACI, ORIC, JPM, SHOP, META and U; KTB upgraded to Buy. Domino’s target was cut.
benzinga.com JP Morgan Maintains Overweight on ORIC Pharmaceuticals, Raises Price Target to $26 JP Morgan analyst Anupam Rama maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight and raises the price target from $23 to $26.
benzinga.com ORIC Pharmaceuticals Announces Agreement With Cancer Research UK To Advance Potential CIP2A-Targeted Therapy Into Clinical Development ORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable targetCancer Research UK to fully fund, sponsor, design, and execute CTA-enabling studies…
globenewswire.com ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development ORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable target Cancer Research UK to fully fund, sponsor, design, and execute CTA-enabling…- benzinga.com Leerink Partners Initiates Coverage On ORIC Pharmaceuticals with Outperform Rating, Announces Price Target of $26 Leerink Partners analyst Asthika Goonewardene initiates coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform rating and announces Price Target of $26.
globenewswire.com ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address…
benzinga.com BTIG Initiates Coverage On ORIC Pharmaceuticals with Buy Rating, Announces Price Target of $26 BTIG analyst Jeet Mukherjee initiates coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy rating and announces Price Target of $26.
seekingalpha.com ORIC Pharmaceuticals, Inc. (ORIC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript ORIC Pharmaceuticals, Inc. (ORIC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
globenewswire.com ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept.
globenewswire.com ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing…- benzinga.com HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $27 HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $25 to $27.
defenseworld.net Dimensional Fund Advisors LP Boosts Holdings in Oric Pharmaceuticals, Inc. $ORIC Dimensional Fund Advisors LP increased its holdings in shares of Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) by 19.9% during the first quarter, according to its most recent disclosure with the…
globenewswire.com ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address…- benzinga.com ORIC Pharmaceuticals Q2 EPS $(0.38) Misses $(0.36) Estimate ORIC Pharmaceuticals (NASDAQ:ORIC) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.36) by 5.56 percent. This is a 19.15 percent increase over losses…
globenewswire.com ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Bayer to provide…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Tenet Healthcare (NYSE:THC) stock increased by 17.3% to $233.54 during Friday's regular session. The market value of their outstanding shares is at $17.4 billion. The company's, Q2 earnings…
seekingalpha.com ORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen The Bull Case ORIC Pharmaceuticals advances rinzimetostat into the global Phase 3 Himalayas-1 trial for mCRPC, with full global rights and royalty-free economics. ORIC's $419.7M cash position funds operations into…
globenewswire.com ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Enozertinib poster presentation to highlight data from an ongoing Phase 1b trial in first-line EGFR atypical NSCLC Rinzimetostat trial-in-progress poster presentation to highlight the ongoing…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Agape ATP (NASDAQ:ATPC) shares rose 17.5% to $2.96 during Wednesday's after-market session. The market value of their outstanding shares is at $2.6 million. China Pharma Holding (AMEX:CPHI)…
- benzinga.com ORIC®Pharmaceuticals Initiates Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat In Combination With NUBEQA Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abirateroneEntered into a clinical trial collaboration and supply agreement with Bayer to provide…
globenewswire.com ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Bayer to provide…
globenewswire.com ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO and SAN DIEGO, July 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address…
benzinga.com Bandwidth, Traws Pharma And Other Big Stocks Moving Lower In Monday's Pre-Market Session Dow futures up 400 points; Bandwidth Inc (BAND) falls after $275M offering; other stocks declining in pre-market trading.- benzinga.com HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $25 Price Target HC Wainwright & Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $25 price target.
- benzinga.com Citigroup Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $16 Citigroup analyst Yigal Nochomovitz maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and lowers the price target from $17 to $16.
- benzinga.com ORIC Pharmaceuticals Presents Multiple Poster Presentation At 2026 American Association For Cancer Research Annual Meeting On Potential Of Rinzimetostat For Prostate Cancer Treatment ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the presentation of…
- benzinga.com HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $25 Price Target HC Wainwright & Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $25 price target.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com What's Behind The Drop In Oric Pharmaceuticals Stock Today? Shares of Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) are tumbling Wednesday after the company announced an update from the Phase 1b trial of rinzimetostat in combination with darolutamide in patients…- benzinga.com Wedbush Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $17 Wedbush analyst David Nierengarten maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and lowers the price target from $20 to $17.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Beyond Meat Posts Downbeat Q4 Results, Joins RH, ORIC Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session US stock futures higher with Dow up 200 pts, Beyond Meat shares drop after downbeat results; ORIC, RH, Aptiv, Sweetgreen, Nike, and others also decline.
benzinga.com Market-Moving News for April 1st NKE: -10% | Nike shares are trading lower after the company reported Q3 financial results. Also, the company issued Q4 sales guidance below estimates. ORIC: -36% | Oric Pharmaceuticals shares are…
benzinga.com Why nCino Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket Shares of nCino Inc (NASDAQ: NCNO) jumped 18% in pre-market trading after reporting strong Q4 results and issuing positive guidance for Q1 and FY27.
benzinga.com ORIC Pharmaceuticals Stock Nosedives 25% After Hours: What Is Going On? ORIC Pharmaceuticals stock rose after reporting positive cancer drug data and advancing to a Phase 3 trial, before falling sharply in after-hours trading.
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com ORIC Pharma Announces Efficacy And Safety Data From Phase 1b Trial Of Once Daily Rinzimetostat In Combination With Darolutamide In Patients With mCRPC Who Were Previously Treated With Abiraterone Rinzimetostat 400 mg once daily selected as RP3D in combination with darolutamide for Himalayas-1 global Phase 3 registrational trial in post-abiraterone mCRPC, with initiation expected in 1H 2026At…